Sanofi, MGH Launch Translational Research Alliance

Sanofi has entered a two-year agreement with Massachusetts General Hospital (MGH) to further translational medicine research and develop new treatments for hematological malignancies and solid tumors. The collaboration will leverage scientific expertise from MGH and Sanofi and will include both preclinical and clinical translational research from proof-of-concept to tolerability and efficacy.

The collaboration will initially involve two early development molecules with promising treatment approaches for various types of advanced tumors. The initial agreement is for two years with the option to extend to a longer term. Financial details were not disclosed.  

“This is a unique model of collaboration and exemplifies our open innovation R&D strategy as well as Sanofi’s approach to make the best use of world-class institutions and scientists within Greater Boston,” said Debasish R. Roychowdhury, M.D., senior vice president and head of Sanofi Oncology. “Our partners at Massachusetts General Hospital are renowned for their basic and translational oncology research accomplishments and we look forward to leveraging our collective strengths to best develop these molecules.”

“Cancer research is at a critical point right now, and we are dedicated to developing new therapeutics that will lead to better treatments and cures,” said Dr. Engelman, an MGH oncologist who specializes in lung cancer. “The creativity and innovative thinking that can come from collaborations between academic medical centers and industry will help transform ideas and early drug development studies into the promise of restored health for patients and families.”